Cologuard is the first and only U.S. Food and Drug Administration-approved noninvasive stool DNA screening test for colorectal cancer. It has been proven to find 92 percent of colorectal cancers in average risk patients.
Mercy is the first hospital in the St. Louis area to make this new option available, according to the report.
More articles on gastroenterology:
CCFA promotes Crohn’s, UC awareness week
14 key players in the endoscopy device market
ASGE awards Lafayette General Endoscopy Center quality certification
